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Psoralen plus UVA (PUVA) is used as a very effective
treatment modality for various diseases, including
psoriasis and cutaneous T-cell lymphoma. PUVA-in-
duced immune suppression and/or apoptosis are
thought to be responsible for the therapeutic action.
However, the molecular mechanisms by which PUVA
acts are not well understood. We have previously
identified platelet-activating factor (PAF), a potent
phospholipid mediator, as a crucial substance trigger-
ing ultraviolet B radiation-induced immune suppres-
sion. In this study, we used PAF receptor knockout
mice, a selective PAF receptor antagonist, a COX-2
inhibitor (presumably blocking downstream effects
of PAF), and PAF-like molecules to test the role of PAF
receptor binding in PUVA treatment. We found that
activation of the PAF pathway is crucial for PUVA-
induced immune suppression (as measured by sup-
pression of delayed type hypersensitivity to Candida
albicans) and that it plays a role in skin inflammation
and apoptosis. Downstream of PAF, interleukin-10
was involved in PUVA-induced immune suppression
but not inflammation. Better understanding of PUVA’s
mechanisms may offer the opportunity to dissect the
therapeutic from the detrimental (ie, carcinogenic)
effects and/or to develop new drugs (eg, using the
PAF pathway) that act like PUVA but have fewer
side effects. (Am J Pathol 2006, 169:795–805; DOI:
10.2353/ajpath.2006.060079)
Psoralen and UVA (PUVA) photochemotherapy consists
of the topical or oral application of a photosensitizing
psoralen (ie, a furocoumarin compound), such as 8-me-
thoxypsoralen, followed by exposure to photoactivating
UVA light.1 PUVA has been used now for more than 2
decades as a very effective therapeutic modality for var-
ious diseases such as psoriasis, chronic eczema, cuta-
neous T-cell lymphoma and other primary and secondary
lymphoproliferative disorders, and cutaneous graft-ver-
sus-host disease after allogeneic stem cell transplanta-
tion. PUVA has strong proapoptotic2 yet profound immu-
nosuppressive effects,3 but the mechanisms by which
PUVA leads to clearance of skin lesions are not well
understood. For many years, the interest in the molecular
effects of PUVA has mainly been focused on the photo-
binding properties of psoralens to DNA, in which pyrim-
idine bases are the main targets for the photochemical
reaction, leading to mono-adducts and/or interstrand
crosslinks.4 However, simple DNA photobinding may not
be sufficient to explain all of the different activities of
PUVA, and thus other targets have been hypothesized.4,5
For instance, unsaturated lipids undergo photobinding
by psoralens as well. Cyclobutane-like adducts are
formed (similar to those between psoralens and thymine)
between one of the reactive double bonds of psoralen
and one or more of the double bonds of fatty acid resi-
dues.4,5 Moreover, PUVA-induced alterations may in-
volve oxidative processes such as the production of ac-
tivated species of oxygen including singlet oxygen.
These highly oxidizing agents can affect various biolog-
ical substrates, including nucleic acids, proteins, and
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lipids. Recent work from our laboratory has shown that
platelet-activating factor (PAF; 1-O-alkyl-2-acetyl-sn-
glycero-3-phosphocholine), a potent phospholipid lipid
mediator, is involved in UVB-induced immune suppres-
sion.6 De novo synthesis of PAF occurs via a two-step
pathway. Phospholipase-A2 enzymatically cleaves ara-
chidonic acid from the sn-2 position of cell membrane
phosphatidylcholine (PC), and an acetyl residue is sub-
sequently transferred to the free hydroxyl from acetyl-
CoA to form biologically active PAF.6 PAF binds to a
specific receptor, a seven transmembrane-spanning G-
coupled protein, found on a variety of PAF-responding
cells, including platelets, monocytes, mast cells, and
polymorphonuclear lymphocytes6 as well as keratino-
cytes.7 In addition to PAF, this receptor also recognizes
structural analogs of PAF, so called PAF-like molecules,
generated by oxidation of PC. Both PAF and PAF-like
molecules have been shown to activate the PAF receptor,
inducing a variety of downstream effects, such as acti-
vation of the mitogen-activated protein kinase pathway
and phospholipases, activating the transcription of cyto-
kine genes and the production of several soluble factors,
such as prostaglandin E2 and interleukin (IL)-10 that play
important roles in cellular communication.6 UVB expo-
sure has also been shown to induce phospholipase A2
activity8 as well as reactive oxygen species, up-regulat-
ing PAF production.9
Based on the knowledge that many of the effects oc-
curring after PUVA exposure (ie, inflammation, immune
suppression, and apoptosis) are also induced by UVB
radiation, and share similar characteristics, we hypothe-
sized that the activation of the PAF pathway may be an
important event in PUVA photochemotherapy. We used
PAF receptor knockout mice, a PAF receptor antagonist,
and a selective COX-2 inhibitor (presumably blocking
downstream effects of PAF), and prospective PAF-like
molecules to test the role of the PAF pathway in PUVA
effects. We found that PAF receptor binding is crucial for




Specific pathogen-free female C3H/HeNCr (MTV) mice
and male and female C57BL/6 mice were purchased
from the National Cancer Institute Frederick Cancer Re-
search Facility Animal Production Area (Frederick, MD).
PAF receptor knockout mice were received from J.
Travers, Department of Dermatology, Indiana University,
Bloomington, IN, and bred in our own animal facility. All
animals were maintained with alternating 12-hour light
and dark cycles and controlled temperature and humidity
in facilities approved by the Association for Assessment
and Accreditation of Laboratory Animal Care Interna-
tional, in accordance with current regulations of the
United States Department of Health and Human Services.
Water and food were provided ad libitum. All animal pro-
cedures were approved by the University of Texas M.D.
Anderson Cancer Center Institutional Animal Care and
Use Committee. Mice were 8 to 20 weeks old at the start
of and were age- and sex-matched within each
experiment.
Reagents
The PAF receptor antagonist PCA-4248 was purchased
from Biomol Research Labs, Inc. (Plymouth Meeting, PA).
Dr. Peter Isakson (G.D. Searle and Co., St. Louis, MO)
provided the selective COX-2 inhibitor SC-236.10 Stock
solutions were prepared by dissolving each in a 50%
dimethyl sulfoxide/phosphate-buffered saline (PBS)
buffer and diluted further in PBS before injection into
mice. The doses of SC-236 (0.2 g per mouse) and
PCA-4248 (500 nmol per mouse) injected intraperitone-
ally immediately before PUVA exposure were based on
previous studies in which these concentrations totally
blocked UV-induced immune suppression.6 Anti-mouse
IL-10 antibody (JES5-2A5.11, rat IgG) (Bioscience, San
Diego, CA) was used for in vivo injection to neutralize
IL-10 activity in mice. As a control, an isotype-matched
antibody (rat IgG antibody; Sigma-Aldrich, St. Louis, MO)
was used. Hen egg yolk PC (L- lecithin) was purchased
from Sigma-Aldrich (catalogue no. P 7718) for ex vivo-in
vivo PC PUVA experiments.
PUVA Treatment
The backs of the mice were shaved with electric clippers
1 day before PUVA treatment. Groups of mice were
painted on their backs with either 100 l of vehicle (100%
ethanol) or 8-MOP (Sigma-Aldrich) in ethanol (at a con-
centration of 1 mg/ml) or were left untreated. The mice
were then kept for 30 minutes in individual compartments
of standard cages, separated with Plexiglas dividers to
allow penetration of 8-MOP. UVA irradiation was provided
by a bank of six F15T8/BLB lamps (emission range, 345
to 400 nm; peak, 365 nm; Sylvania, Danvers, MA). During
UVA irradiation, the mice were housed five per cage,
individually separated, on a shelf 20 cm below the fluo-
rescent light bulbs under a wire cage top. The mice were
UVA-irradiated at a mean UVA irradiance of 4.5 mW/cm2,
as measured by an IL 700 spectroradiometer with a SEE
033 UVA detector (International Light Inc., Newburyport,
MA). Solar-simulated UV radiation was provided by an
Oriel 1000 W xenon solar simulator (Oriel, Stanford, CT)
with a set-up and dose monitoring, as previously de-
scribed.11 For certain delayed type hypersensitivity
(DTH) experiments a thin layer of PC (5 mmol/L in PBS)
supplemented or not with 8-MOP (at a final concentration
of 1 mg/ml) was spread into a polystyrene dish and
exposed to different doses of UVA radiation of the F15T8/
BLB lamps, under conditions as used for PUVA treatment
of mice in vivo, as outlined above. PUVA- or UVA-treated
solutions of PC are referred as to PUVA-PC or UVA-PC.
PUVA-PC and UVA-PC were used for intraperitoneal in-
jection into mice 5 days before sensitization with Candida
albicans in DTH experiments.
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Quantification of Macroscopic Skin Inflammation
Inflammation was assessed by measuring the double
skin-fold thickness12 of dorsal skin of the mice with a
spring-loaded engineer’s micrometer (Swiss Precision In-
struments, Garden Grove, CA) before and at different
time points after PUVA, UVA, or solar-simulated UV treat-
ment. To determine the minimal inflammatory PUVA dose,
groups of mice were PUVA-treated with double-dose in-
crements. Skin swelling was determined for individual
mice by subtracting the double skin-fold thickness before
PUVA treatment from that after PUVA treatment. The skin
swelling values of individual mice were averaged for the
different treatment groups. The minimum inflammatory
PUVA dose was defined as the minimum dose required to
elicit statistically significant skin swelling in PUVA-treated
mice.
DTH
Mice were treated with PUVA on day 0. Five days later
they were immunized by the subcutaneous injection of
2  107 formalin-fixed C. albicans into each flank. Nine
days later, each hind footpad was measured with the
engineer’s micrometer, the thickness was recorded, and
the animals were challenged by injecting 50 l of Can-
dida antigen (Antigen Supply House, Northridge, CA) into
each hind footpad. Thickness of each hind footpad was
measured again 18 to 24 hours later and the mean foot-
pad swelling for each mouse (left foot  right foot/2) was
recorded. The mean footpad swelling  SD was calcu-
lated for each experimental group. The specific footpad
swelling was calculated by subtracting the mean footpad
swelling found in control mice that were not immunized,
but were challenged, from the swelling observed in
groups of mice that were both immunized and chal-
lenged. The percent suppression of DTH was determined
by the following formula: [1  (A/B)]  100, where A
represents the specific footpad swelling in sensitized and
PUVA (or solar-simulated UV)-treated mice (ie, experi-
mental group), and B represents that in sensitized, unir-
radiated mice (ie, positive control group).
Histological Examination
Two to three mice per treatment group were sacrificed
before and at various time points (24, 48, 72, 120, and
360 hours) after PUVA exposure. Approximately 1 cm2 of
dorsal skin was excised per mouse, fixed immediately in
4% buffered formaldehyde, processed routinely, and
sectioned at 5 m for hematoxylin and eosin (H&E) stain-
ing. At least two nonsequential sections of each speci-
men were examined for histological alterations. Sunburn
cells were counted in the interfollicular epidermis in a
total of at least 10 random high-power fields per section
(at 100 microscopic magnification). Counts were ex-
pressed as the number of sunburn cells per centimeter
length of epidermis, as determined with a calibrated eye-
piece micrometer (Nikon Inc., Garden City, NY). Epider-
mal hyperplasia was assessed by counting epidermal
cell layers and measuring the thickness of the epidermis
from the basal layer to the stratum corneum with the
eyepiece micrometer. A total of at least 10 measurements
per section were made at randomly selected sites. To
quantitate inflammatory cellular infiltration in the dermis of
the specimens, an eyepiece counting grid (Olympus,
Vienna, Austria) was used at 200 microscopic magnifi-
cation. The grid provided an area of 0.04 mm2. The grid
was placed at 10 randomly selected dermis locations per
specimen. All infiltrating cells (including leukocytes, mac-
rophages, and fibroblasts) within the grid were counted.
The counts were averaged per specimen and then mul-
tiplied by 25 to give the total number of cells per mm2.
Terminal dUTP Nick-End Labeling (TUNEL)
Assay
Five-m sections of paraffin-embedded skin tissue were
deparaffinized, and TUNEL assay was performed using a
commercial kit according to the manufacturer’s protocol
(Promega Corp., Madison, WI).
Immunohistochemical p53 Staining
Deparaffinized 5-m tissue sections were used for immu-
nohistochemical p53 staining, as described previously.13
Immunohistochemical IL-10 Protein Staining
Deparaffinized 5-m tissue sections were placed in a
humid chamber, and endogenous peroxidase was
blocked with 3% hydrogen peroxide. Slides were incu-
bated with protein blocking solution (5% horse serum in
1% normal milk made from 1 g of milk powder in 100 ml
of PBS) for 30 minutes at room temperature, followed by
overnight treatment at 4°C with diluted (5 g/ml) goat
anti-mouse IL-10 monoclonal antibody (R&D Systems,
Minneapolis, MN). The slides were washed and incu-
bated with biotin-labeled diluted (2 g/ml) swine anti-
goat antibody (Boehringer Mannheim, Indianapolis, IN)
for 40 minutes, with peroxidase-labeled streptavidin for
30 minutes, and with diaminobenzidine (Research Genet-
ics, Huntsville, AL) for 5 to 10 minutes. Sections were
counterstained with hematoxylin.
IL-10 Enzyme-Linked Immunosorbent Assay
(ELISA)
Two to three mice per treatment group were bled at
various time points (24, 48, 72, and 120 hours) after
PUVA exposure. Serum levels of IL-10 were measured by
Opteia mouse IL-10 ELISA kit (Pharmingen, San Diego,
CA), according to the manufacturer’s instructions. The
minimum detectable dose of IL-10 was 125 pg/ml.
Image Analysis
Photographs of p53-stained sections were subjected to
computerized, digitized image analysis. Optimate image
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analysis software version 6.2 (Media Cybernetics, Silver
Spring, MD) was used to quantify the staining. At least
three photographs were used per section and sample.
The amount of specific antibody binding was visualized
and quantified by image analysis and expressed in terms
of integrated mean optical density of a cell nucleus. The
nuclear staining in at least 100 representative nuclei was
measured per specimen.
Statistical Analysis
The readings of the DTH experiments as well as histolog-
ical and immunohistochemical stainings were conducted
in a blinded manner. All data presented are expressed as
means  SD. Statistical differences among control and
experimental groups were determined by use of analysis
of variance (StatView 5.01; SAS Institute Inc., Cary, NC).
Statistical significance was set at a P level 0.05.
Results
Determination of the Minimal Phototoxic PUVA
Dose
PUVA is used for the treatment of skin diseases such as
psoriasis at sub- and/or near erythematogenic dosages.
For instance, the original European PUVA study protocol
calls for the minimal phototoxic dose (MPD) as the start-
ing dose for PUVA treatment. The MPD is determined in a
test, in which the skin of patients is exposed to a test
ladder of increasing UVA dosages after topical and/or
oral psoralen administration.1,14 The MPD is defined as
the smallest UVA dose required to produce a clearly
demarcated and perceptible erythema, as determined 48
to 120 hours after psoralen administration. To assure that
we used clinically relevant PUVA dosages in the experi-
ments, we performed kinetic and dose-response studies
to determine the MPD in mice. Because erythema is
difficult to read in the pigmented skin of C3H and
C57BL/6 mice, skin swelling was used as a surrogate end
point for PUVA-induced inflammation and erythema.
Those studies revealed that maximum skin swelling was
present in mice 48 hours after PUVA exposure and the
MPD in the C3H mice as well as C57BL/6 mice was 50
kJ/m2 (data not shown). This dosage falls in the range of
MPD values found in patients in the clinical set-up of
minimal phototoxicity testing.
PUVA-Induced PAF Receptor Activation Is
Crucial for PUVA-Induced Immune Suppression
We used the mouse model of induction of DTH to inves-
tigate the effect of different PUVA doses on immune
function in the mice. Whereas significant inflammation (ie,
skin swelling) after PUVA was observed in mice exposed
to 50 kJ/m2 (Figure 5a), significant immune suppression
was observed at 25 kJ/m2 (Figure 1a), indicating that
higher PUVA doses are necessary to induce inflammation
than immune suppression. Because in the clinic the dose
Figure 1. PUVA-induced PAF receptor activation is crucial for PUVA-induced
immune suppression. PUVA-induced systemic immune suppression was
studied in the model of DTH to C. albicans. Groups of C3H, C57BL/6, or PAF
receptor knockout mice (n 5 to 6 per group) were left untreated or treated
with topical 8-MOP and different doses of UVA, ranging from 6.25 to 50
kJ/m2, solar-simulated UV radiation (15 kJ/m2), or were injected with PUVA-
treated, UVA-treated, or untreated PC 5 days before immunization with C.
albicans. Nine days later the mice were challenged with Candida antigen.
DTH was measured 24 hours after challenge. The background response
(negative control) was measured in mice that were not immunized but
challenged. Mice that were immunized (but not PUVA-treated) and chal-
lenged served as positive control group. PUVA exposure was highly immu-
nosuppressive and suppressed DTH by up to more than 90% at the PUVA
dose of 50 kJ/m2. a: The intraperitoneal injection of C3H mice immediately
before PUVA exposure with either the PAF receptor antagonist PCA-4248 or
the COX-2 inhibitor SC-236 totally blocked PUVA-induced immune suppres-
sion. *P  0.0001; P  0.0005; #P  0.01 versus positive control group. b:
C57BL/6 (WT) but not PAF receptor knockout (PAFR/) mice were sus-
ceptible to immune suppression induced by either PUVA at a dose of 50
kJ/m2 or solar-simulated UV at 15 kJ/m2. *P  0.005; P  0.05 versus
respective positive control group. c: The injection of C3H mice with PUVA-
treated PC 5 days before sensitization with C. albicans resulted in significant
immune suppression, in a dose-dependent manner similar to that in the in
vivo PUVA experiments. The injection of UVA-treated PC (without psoralen)
also led to immune suppression in a very similar dose-dependent manner
than PUVA-treated PC. *P  0.0001; P  0.005; #P  0.01 versus positive
control group.
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of PUVA used is based on the minimal inflammatory
dose, in subsequent studies we chose to use 50
kJ/m2, which induces both immune suppression and
inflammation.
To test the hypothesis that, similar to UVB exposure,
PAF receptor activation may be involved in PUVA-in-
duced immune suppression, we injected C3H mice in
DTH experiments with the selective PAF receptor antag-
onist PCA-4248 and the selective COX-inhibitor SC-236,
presumably blocking effects downstream of PAF activa-
tion (ie, PAF induction of COX-2).15 As evident from Fig-
ure 1a, the intraperitoneal injection of mice immediately
before PUVA exposure with either the PAF receptor an-
tagonist or the COX-2 inhibitor nearly completely blocked
PUVA-induced immune suppression. The injection of the
dimethyl sulfoxide/PBS vehicle did not significantly affect
PUVA-induced immune suppression in any experiment
(data not shown).
However, because certain PAF antagonists have been
shown to have dual activities in blockading PAF receptor-
mediated activation and also inhibiting other enzymes,
including COX, lipoxygenase, phospholipase A2, acetyl-
cholinesterase, and intracellular PAF acetylhydrolase,16
we have used PAF receptor knockout mice to substanti-
ate the significance of the PAF pathway in PUVA-induced
immune suppression. PAF receptor knockout mice,
which have been created by targeted gene disruption of
the PAF receptor gene in E14-1 embryonic stem cells
derived from 129/Ola mouse on C57BL/6 genetic back-
ground, do not show gross morphological abnormalities
in any organ system, including the skin.16 Figure 1b
shows that exposure to PUVA at a dose of 50 kJ/m2 or
solar-simulated UV radiation at a dose of 15 kJ/m2 did not
lead to significant immune suppression in PAF receptor
knockout mice but only in their C57BL/6 wild-type litter-
mates, substantiating the importance of an intact PAF
pathway for immune suppression.
To test the hypothesis that not only PUVA-induced PAF
itself but also PUVA-induced PAF-like molecules can lead
to immune suppression, we performed an ex vivo-in vivo
PUVA experiment with PC. PC was treated in vitro in the
presence or absence of 8-MOP with different UVA doses
before intraperitoneal injection into C3H mice. Similarly
on UVB exposure6 this presumably may lead to the for-
mation of PAF-like molecules. These studies revealed
that PUVA-treated PC on intraperitoneal injection 5 days
before sensitization with C. albicans led to suppression of
DTH in a dose-dependent manner, similar to that after in
vivo PUVA treatment of the mice (Figure 1c), suggesting
that PUVA-induced PAF-like molecules may indeed be
involved in PUVA-induced immune suppression. How-
ever, intraperitoneal injection of UVA-treated PC alone
(without psoralen) surprisingly led to immune suppres-
sion in a similar dose-dependent manner compared to
PUVA treatment. This contrasted the finding that the very
same UVA doses that were used in the PC experiment
did not led to immune suppression in the pure in vivo
PUVA experiment (Figure 1a). The reasons for this dis-
crepancy remain unclear at present; however, possible
explanations are outlined in the Discussion. Importantly,
the intraperitoneal injection of UVA-PC in the presence or
absence of psoralen did not led to inflammation of the
skin, as measured by skin swelling (data not shown).
Taken together, these findings unambiguously indicate
that PUVA-induced immune suppression and inflamma-
tion follow overlapping but not identical pathways.
IL-10 Is Involved Downstream of PAF Receptor
Activation in PUVA-Induced Immune
Suppression but Not Inflammation
Next, we investigated which events may be involved in
PUVA-induced immune suppression downstream of
PAF. We hypothesized that similar to UVB17 IL-10 may
be involved in PUVA-induced immune suppression.
First, we demonstrated by immunohistochemical stain-
ing that PUVA exposure led to up-regulation of IL-10 in
the skin of C3H mice in situ. IL-10 protein was in-
creased in the skin starting at 24 hours (Figure 2a) and
remained elevated to a similar degree up to 120 hours
(data not shown) after PUVA exposure. ELISA of serum
taken from the mice at different time points after PUVA
exposure revealed that PUVA also led to an increase of
serum IL-10 at 120 hours after exposure (Figure 2b).
Importantly, the injection of either the PAF antagonist
PCA-4248 or the COX-2 inhibitor SC-236 nearly com-
pletely blocked PUVA-induced up-regulation of IL-10 in
skin and serum (Figure 2, a and b). Next we deter-
mined if there was a functional role for IL-10 in PUVA-
induced immune suppression in the DTH model. Injec-
tion of C3H mice with anti-IL-10 antibody abrogated
PUVA-induced immune suppression whereas injection
of an isotype-matched antibody had no significant ef-
fect (Figure 2c). In contrast, the administration of anti-
IL-10 antibody did not significantly affect the PUVA-
induced skin-swelling response (Figure 5b), indicating
once more that immune suppression and inflammation
involve overlapping but different mechanisms.
PAF Receptor Activation Is Involved in PUVA-
Induced Apoptosis Possibly by Interfering with
p53
PUVA-induced apoptosis of specific target cells such as
keratinocytes, Langerhans cells, and/or lymphocytes
within the skin is considered as one of the possible mech-
anisms involved in the therapeutic action of PUVA in skin
diseases.2 We therefore asked the question whether
blockade of the PAF pathway may also influence PUVA-
induced apoptosis. TUNEL staining of skin of C3H mice
showed that PUVA-induced apoptosis of keratinocytes
could be diminished by intraperitoneal injection of mice
with either the PAF receptor antagonist PCA-4248 or the
COX-2 inhibitor SC-236 (Figure 3). The crucial role of the
PAF pathway in PUVA-induced apoptosis also became
evident by the effect of both the PAF receptor antagonist
and the COX-2 inhibitor on PUVA-induced sunburn cell
formation. Sunburn cells are considered as the hallmark
of apoptosis.12 As evident from the results of examination
of H&E-stained skin sections of mice both the PAF an-
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tagonist PCA-4248 and the COX-2 inhibitor SC-236
nearly completely blocked PUVA-induced sunburn cell
formation (Table 1). The p53 gene and protein takes a
crucial position in apoptosis in general by stopping the
cell cycle to allow DNA repair after damage, so therefore
we asked how blockade of PAF-receptor activation might
influence the p53 status. Immunohistochemical p53 pro-
tein staining of murine skin revealed that PUVA-induced
up-regulation of p53 protein could be diminished by the
administration of either the PAF receptor antagonist PCA-
4248 or the COX-2 inhibitor SC-236 (Figure 4).
PAF Pathway Blockade Can Reduce PUVA-
Induced Inflammation
Finally, we were interested in determining how blocking
PAF receptor binding affects PUVA-induced inflamma-
tion. This is an important clinical question because acci-
dental PUVA overdosage can result, 2 to 3 days later, in
severe, life-threatening phototoxic burning of the skin,
and presently, no effective treatment is available. In C3H
mice blocking the activation of the PAF pathway by using
either a PAF receptor antagonist PCA-4248 or targeting a
downstream effect (by the COX-2 inhibitor SC-236) not
only reduced PUVA-induced macroscopic skin swelling
(as the clinical sign of PUVA phototoxicity) (Figure 5a),
but also clearly diminished inflammatory skin infiltration
(by up to 90%) and hyperplasia (by up to 95%) on the
microscopic level (Figure 6 and Table 1). However,
whereas both the PAF receptor antagonist and the COX-2
Figure 2. IL-10 is essential downstream of PAF receptor activation for PUVA-
induced immune suppression. a: PUVA-induced IL-10 protein expression in
the skin of C3H mice was studied by immunohistochemical anti-IL-10 stain-
ing. Note that there is diffuse brownish staining (indicating the presence of
IL-10 protein) of keratinocytes and dermal cells in PUVA-treated skin. The
intraperitoneal injection of mice immediately before PUVA exposure either
with the PAF receptor antagonist PCA-4248 or the COX-2 inhibitor SC-236
inhibited PUVA-induced IL-10 up-regulation in the skin. Only patchy epider-
mal staining and occasional IL-10-positive dermal cells were present in the
skin of mice injected with either the PAF receptor antagonist or the COX-2
inhibitor, similar to the staining pattern observed in untreated control mice
(none) or UVA- or 8-MOP-treated mice. Photographs shown are from skin
samples taken 24 hours after PUVA exposure to 50 kJ/m2. b: There was
significant p53 up-regulation of IL-10 protein (as measured by ELISA) in the
serum at 120 hours after PUVA exposure to 50 kJ/m2. This IL-10 up-regula-
tion was not found in serum of mice injected immediately before PUVA
exposure with either the PAF receptor antagonist or the COX-2 inhibitor. n
2 to 3 mice per group. c: Immune function was studied in the model of DTH
to C. albicans (for description of positive and negative control group see
legend of Figure 1). The intraperitoneal injection of mice immediately before
PUVA exposure with an anti-IL-10 antibody abrogated PUVA-induced im-
mune suppression, whereas an isotype control antibody had no significant
effect. n  5 mice per group. *P  0.0001; P  0.05 versus positive control
group.
Figure 3. PAF receptor activation is involved in PUVA-induced apoptosis.
Apoptosis was determined by TUNEL staining. Results shown are from skin
samples taken 24 hours (time point of maximum effect) after PUVA exposure
to 50 kJ/m2. PUVA-induced apoptosis (green nuclear staining; right) was
diminished in the skin of mice injected intraperitoneally immediately before
PUVA exposure with either the PAF receptor antagonist PCA-4248 or the
COX-2 inhibitor SC-236. The left panel (red nuclear staining) shows the
propidium iodide controls. Treatment with UVA or 8-MOP alone did not lead
to significant levels of apoptosis.
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inhibitor more consistently protected against PUVA-in-
duced immune suppression, they variably protected
against inflammation (Figure 5b). We also looked for
PUVA-induced and solar-simulated UV radiation-induced
inflammation in PAF receptor knockout mice. Both PUVA
and solar-simulated UV led to significant skin inflamma-
tion (as measured by skin swelling) surprisingly with no
difference between PAF receptor knockout mice and
their wild-type controls for both treatments (Figure 5c). In
a control experiment, we used phorbol myristate acetate
(PMA) (75 l of a 200 g/ml acetone solution per mouse
applied topically to dorsal skin) to induce inflammation
but did not find a difference either in the skin-swelling
response between PAF receptor knockout mice and their
wild-type controls (data not shown).
Discussion
This study revealed that PAF receptor binding is a crucial
event in PUVA-induced immune suppression (Figure 1)
and involved in other PUVA-induced effects, including
IL-10 production (Figure 2), apoptosis (Figure 3), p53
up-regulation (Figure 4), and inflammation (Figures 5 and
6; and Table 1). Downstream of PAF activation, IL-10
seems to be involved in immune suppression but not
inflammation. This finding is consistent with the role of this
cytokine in UVB radiation-induced immune suppres-
sion,17 in which PAF has been shown to activate the
transcription of COX-2 and IL-10, two important immuno-
logical mediators.6 Previous studies from our laboratory
suggest that an early step in the UV-induced cytokine
cascade is PGE2 production, which then causes down-
stream effects, including the secretion of IL-4 and IL-
10.18 We also know from previous work that application of
other dermal immunotoxic agents, such as jet fuel in-
duces immune suppression via a PAF-, COX-2-, and
IL-10-dependent mechanism.19,20 Many PUVA-induced
effects (including immune suppression) may be attribut-
able to the generation of PAF and/or PAF-like molecules
by degradation of PC by reactive oxygen species.9 For
instance, phospholipase-A2, a key enzyme in PAF pro-
duction, can be induced by UVB exposure8 and possibly
also by PUVA.21,22 The possibility that reactive oxygen
species-associated effects are responsible for PUVA-in-
duced effects such as immune suppression is supported
by the observation that the antioxidative polypodium leu-
cotomos extract has been shown to inhibit PAF produc-
tion23 and several types of UV and/or PUVA-induced
immunological alterations, such as depletion of antigen-
presenting Langerhans cells in human skin.24 Moreover,
the isoflavone genistein, a specific inhibitor of tyrosine
kinase, has been shown to inhibit chemical carcinogen-
induced reactive oxygen species and PUVA-induced
photodamage, including inflammatory skin changes such
as dermal neutrophilic and lymphocytic infiltration.25
We observed that ex vivo PUVA-treated and UVA-
treated PC but not unirradiated PC induced immune sup-
pression in a dose-dependent manner (Figure 1c). Sur-
prisingly however, there was no difference in the UVA
dose response dependency or the UVA threshold dose
for immune suppression, irrespective whether or not pso-
ralen was added to the UVA-irradiated PC solution before
UVA irradiation. In contrast, the same PUVA, but not UVA,
doses did induce immune suppression in the in vivo ex-
periment (Figure 1a). This observation suggests that
PUVA and UVA ex vivo treatment of PC produce PAF-like
molecules (presumably via oxidative damage) that in-
duce immune suppression. It also suggests that addi-
tional events (for instance DNA damage)6 may be nec-
essary and/or prerequisite for immune suppression,
which only occurs after PUVA (but not UVA only) treat-
ment in vivo. For example, UVB-induced DNA damage
activates mitogen-activated protein kinase p3826 which
may initiate a cascade of events, including cell-cycle
arrest at the G2/M checkpoint (to allow for DNA repair)
and the activation of phospholipase-A2,27 the first enzy-
matic step of PAF synthesis.6 A similar scenario might
take place on PUVA exposure. Alternatively, we suggest
that PUVA treatment may inhibit detoxifying mechanisms
involved in PAF degradation (for instance by PAF-acetyl-
hydrolase)28 and therefore may lead to immune suppres-
sion that may not occur after in vivo UVA treatment.
The observation that IL-10 is involved downstream of
PAF in PUVA-induced immune suppression (Figure 2) is
intriguing because recombinant IL-10 has been shown to
be clinically effective in the treatment of psoriasis,29 one











None 0.0  0 1.8  0 26.9  4.4 513  18
8-MOP 0.0  0 1.8  0 26.6  1.1 596  101
UVA 1.3  1.8 1.8  0 32.8  8.2 534  48
PUVA 45  14.4* 4  0.4* 121.7  5.0* 1075  60*
PUVA  PCA-4248 2.5  1.8 2.5  0.8 40.4  10.5 741  164
PUVA  SC-236 0.0  0 2  0.1 31.7  1.8 625  131
Groups of C3H mice were treated with PUVA, 8-MOP, or UVA alone. The UVA dose used was 50 kJ/m2. Immediately before PUVA exposure,
certain groups of mice were injected intraperitoneally with either the PAF receptor antagonist PCA-4248 or the COX-2 inhibitor SC-236. Two to three
mice per treatment group were killed at various time points after PUVA exposure (24, 48, 72, 120, and 360 hours). Data shown are from days with the
maximum PUVA effect for a specific histological parameter; ie, sunburn cells (SBCs) at 24 hours; number of epidermal skin layers, skin thickness, and
total dermal cell density at 48 hours after PUVA exposure.
*P  0.05 versus untreated control group (none).
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of the diseases most often treated by PUVA.1,14 The
clinical response to IL-10 in patients with psoriasis was
associated with a significant decrease of cutaneous T-
cell infiltration and the lesional expression of type 1 cy-
tokines such as interferon- and tumor necrosis factor-.
IL-10 inhibited the epidermal IL-8 pathway by down-
regulating the expression of this potent chemoattractant
and its receptor CXCR2.29 On the other hand, activation
of the epidermal PAF receptor, for instance by UVB radi-
ation, can also lead to the production of IL-8.15,30 How-
ever, different dose levels of an immunotoxic agent such
as UVB and/or PUVA may be responsible for an ambiv-
alent outcome in cytokine regulation. For instance, su-
praerythemal inflammatory doses of UVB and/or PUVA
exposure may lead to a predominance of inflammatory
cytokines such as IL-6 and IL-8, whereas suberythemal
or near-erythemal doses of exposure (as used in the
model of this study) may rather lead to the production of
immunomodulatory cytokines such as IL-431 and IL-10.
This goes well in line with the clinical knowledge that
suberythemal PUVA exposure is beneficial for psoriasis
but exposure to PUVA above the phototoxicity dose can
lead to aggravation of the disease by a process called
koebnerization.32
The finding that PAF pathway blockade (Figure 3) does
reduce PUVA-induced apoptosis33,34 is intriguing as
well, because the proapoptotic effect of PUVA may con-
tribute to the treatment’s clinical efficacy at least in cer-
tain PUVA-responsive diseases.2 For instance, PUVA can
selectively induce cell-cycle arrest and subsequent apo-
ptosis in human T lymphocytes,2,35 a process that might
be particularly important for therapeutic efficacy in cuta-
neous T-cell lymphoma.36,37 Previous work from our lab-
oratory using knockout mice has shown that p53 and
Fas/Fas ligand interactions are required for PUVA-in-
duced apoptosis in epidermal cells.2 Interestingly, how-
ever, in a recent study induction of psoriasis was inhib-
ited in a mouse xenotransplantation model by injection of
blocking anti-Fas or anti-Fas ligand antibody.38 Impor-
tantly, in the present study the reduction of apoptosis was
paralleled by inhibition of p53 protein expression in the
epidermis (Figure 4). A role for the PAF pathway in apo-
ptosis on PUVA exposure is consistent with a role for PAF
in apoptosis induction by UVB. Barber and colleagues7
have reported that the expression of PAF receptor re-
sulted in enhanced UVB radiation-induced apoptosis in a
human epidermal cell line, consistent with very recent in
vivo findings in PAF receptor knockout mice by the same
group of investigators (Travers JB, Zhang Q, Konger RL:
Involvement of the platelet-activating factor system in
ultraviolet B-radiation-mediated cytokine production,
apoptosis, and immunosuppression. Abstract presented
at the 67th Annual Meeting of the Society for Investigative
Dermatology, May 3 to 6, 2006 Philadelphia, PA). Inter-
estingly, however, Brewer and colleagues39 have shown
that PAF can have anti- and proapoptotic effects in cells,
initiated by its G-protein-coupled receptor or occurring
independently of this receptor. Furthermore, Southall and
colleagues40 have shown that the activation of the epi-
dermal PAF receptor protected from apoptosis induced
by either TNF- or TNF-related apoptosis-inducing ligand
and that this protective effect was inhibited by pretreat-
ment with PAF receptor antagonists mediated by a nu-
clear factor-B-dependent pathway.
Figure 4. PAF receptor activation is also involved in PUVA-induced p53
up-regulation. PUVA-induced p53 protein expression in the skin of mice was
studied by immunohistochemical staining. Results shown are from skin
samples taken 24 hours (time point of maximum effect) after PUVA exposure
to 50 kJ/m2. a: PUVA-induced p53 up-regulation (brownish nuclear staining)
was reduced in the skin of mice injected intraperitoneally immediately before
PUVA exposure with either the PAF receptor antagonist PCA-4248 or the
COX-2 inhibitor SC-236. Treatment with UVA or 8-MOP alone did not lead to
significant apoptosis. b: Computerized image analysis quantifying the optical
density of nuclear staining of epidermal cells revealed that the effect of the
PAF receptor antagonist and the COX-2 inhibitor on PUVA-induced p53
expression was stronger than evident from the differences in the numbers of
p53-positive epidermal cells in a. n 2 to 3 mice per group. *P 0.05 versus
8-MOP- or UVA-treated mice.
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Our study also showed that blockade of the PAF path-
way reduced inflammation and hyperplasia of the skin in
C3H mice (Figure 5, a and b; Figure 6; and Table 1).
These findings are consistent with the results of studies in
which PAF receptor antagonists have been shown to
modulate neutrophil responses with thermal injury in rat
skin in vivo41 and inhibit UVB-induced inflammation in
mouse ears.42 PUVA can lead to severe phototoxic side
effects, and although these effects are rarely lethal, are
painful and are observed after accidental PUVA over-
dose.43 We suggest that the administration of selective
COX-2 inhibitors and/or PAF receptor antagonists may be
clinically useful to suppress PUVA-induced acute and
chronic phototoxicity. Importantly, in a long-term study
in hairless mice, the PAF antagonist PCA-4248 and
COX-2 inhibitor SC-236 not only reduced PUVA-in-
duced chronic inflammation and hyperplasia but also
suppressed carcinogenesis (P. Wolf, D.X. Nghiem, J.P.
Walterscheid, S. Byrne, H.N. Ananthaswarmy, and S.E.
Ullrich, unpublished preliminary data). In view of the
detected anti-apoptotic effect of PAF inhibition, this
anti-carcinogenic effect is intriguing but may be attrib-
utable to simultaneous reduction of inflammation
and/or immune suppression after PAF antagonist ap-
plication. Interestingly however, PUVA and solar-simu-
lated UV exposure led to significant inflammation (as
measured by skin swelling) with no difference between
PAF receptor knockout mice and their wild-type litter-
mates for both treatments (Figure 5c). This seems to be
a general phenomenon (not only related to PUVA and
UV) because a similar result was observed when we
used PMA to induce inflammation in a control experi-
ment. However, taken together with the results of the
studies with the PAF receptor antagonist PCA-4248
Figure 5. PAF pathway blockade does reduce skin inflammation on the macroscopic level. a: Groups of C3H mice (n  5 per group) were treated with topical
8-MOP and/or different doses of UVA, ranging from 6.25 to 50 kJ/m2. Skin swelling was determined by measuring double skin-fold thickness of dorsal skin of
the mice before and at 48 hours after PUVA exposure. The skin swelling data are from the DTH experiment presented in Figure 1a. The skin swelling response
was greatly diminished in the skin of mice injected intraperitoneally immediately before PUVA exposure with either he PAF receptor antagonist PCA-4248 or the
COX-2 inhibitor SC-236. Note that treatment with UVA or 8-MOP alone did not lead to significant skin swelling. *P  0.05 versus none (no treatment). b: Both
the PAF antagonist PCA-4248 and the COX-2 inhibitor SC-236 more consistently protected in repeat experiments against PUVA-induced immune suppression, but
they gave only variable protection against inflammation (at the dose of 50 kJ/m2). This is evident from the plotted graphs showing mean skin swelling (top graph)
versus mean percent immune suppression (bottom graph). Results are means from several independent experiments (n  2 to 7 per treatment with at least five
mice per experimental group per experiment). *P 0.01 versus 8-MOP- or UVA-treated mice (top graph). *P 0.0005 versus 8-MOP- or UVA-treated mice (bottom
graph). c: Swelling of dorsal skin was also determined in PAF receptor knockout mice (PAFR/) and their C57BL/6 littermates (WT) at 48 hours after exposure
to PUVA at a dose of 50 kJ/m2 or solar-simulated UV (ssUV) radiation at a dose of 15 kJ/m2. The presented skin swelling data are means from three independent
experiments with at least five mice per experimental group per experiment. *P  0.01; P  0.05 versus respective untreated control group (none).
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and the COX-2 inhibitor SC-236 in C3H mice (Figure
5b), this indicated that inflammation is less susceptible
than immune suppression to blockade of the PAF
pathway.
A better understanding of PUVA’s mechanisms is of
great clinical importance because it is a highly effective
clinical treatment for a large number of diseases and
remains the best therapeutic modality for early stages of
cutaneous T-cell lymphoma44 and severe forms of psori-
asis, despite the introduction of new treatments such as
the biologics.32,45,46 For instance, we have recently
shown that PUVA treatment resulted in the reduction of
psoriasis activity severity index of greater than 75% (now
considered as gold standard of therapeutic response) in
more than 90% of patients with psoriasis,14 a result,
which is hardly obtained with any other type of anti-
psoriatic treatment. Therefore it seems highly desirable to
investigate how the agents described here affect PUVA’s
therapeutic efficacy using newly available animal models
of psoriasis47–51 and eczema.52 A better understanding
of PUVA’s mechanisms may not only offer the opportunity
to dissect the beneficial (ie, therapeutic) effects from the
detrimental (ie, carcinogenic) side effects53,54 but also
lead to the development of new drugs (eg, using the PAF
pathway) acting like PUVA but having less side effects.
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